vs

Side-by-side financial comparison of Chaince Digital Holdings Inc. (CD) and Keros Therapeutics, Inc. (KROS). Click either name above to swap in a different company.

Chaince Digital Holdings Inc. is the larger business by last-quarter revenue ($466.6K vs $385.0K, roughly 1.2× Keros Therapeutics, Inc.).

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for hematological disorders, musculoskeletal diseases and anemia, serving underserved patient groups with unmet medical needs from its core U.S. base.

CD vs KROS — Head-to-Head

Bigger by revenue
CD
CD
1.2× larger
CD
$466.6K
$385.0K
KROS

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
CD
CD
KROS
KROS
Revenue
$466.6K
$385.0K
Net Profit
$-3.0M
Gross Margin
Operating Margin
-665.1%
Net Margin
-640.5%
Revenue YoY
-87.3%
Net Profit YoY
49.0%
EPS (diluted)
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CD
CD
KROS
KROS
Q4 25
$385.0K
Q3 25
$14.3M
Q2 25
$466.6K
$18.2M
Q1 25
$211.2M
Q3 24
$388.0K
Q2 24
$37.0K
Q1 24
$83.0K
Q3 23
$8.0K
Net Profit
CD
CD
KROS
KROS
Q4 25
Q3 25
$-7.3M
Q2 25
$-3.0M
$-30.7M
Q1 25
$148.5M
Q3 24
$-53.0M
Q2 24
$-45.3M
Q1 24
$-43.1M
Q3 23
$-39.4M
Operating Margin
CD
CD
KROS
KROS
Q4 25
Q3 25
-107.9%
Q2 25
-665.1%
-219.2%
Q1 25
72.0%
Q3 24
-15117.8%
Q2 24
-136321.6%
Q1 24
-58413.3%
Q3 23
-541000.0%
Net Margin
CD
CD
KROS
KROS
Q4 25
Q3 25
-51.0%
Q2 25
-640.5%
-169.0%
Q1 25
70.3%
Q3 24
-13648.5%
Q2 24
-122316.2%
Q1 24
-51944.6%
Q3 23
-493000.0%
EPS (diluted)
CD
CD
KROS
KROS
Q4 25
Q3 25
$-0.18
Q2 25
$-0.05
$-0.76
Q1 25
$3.62
Q3 24
$-1.41
Q2 24
$-1.25
Q1 24
$-1.21
Q3 23
$-1.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CD
CD
KROS
KROS
Cash + ST InvestmentsLiquidity on hand
$27.2M
$287.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$29.4M
$303.1M
Total Assets
$36.6M
$338.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CD
CD
KROS
KROS
Q4 25
$287.4M
Q3 25
$693.5M
Q2 25
$27.2M
$690.2M
Q1 25
$720.5M
Q3 24
$530.7M
Q2 24
$405.9M
Q1 24
$442.4M
Q3 23
$287.9M
Stockholders' Equity
CD
CD
KROS
KROS
Q4 25
$303.1M
Q3 25
$703.6M
Q2 25
$29.4M
$706.7M
Q1 25
$728.9M
Q3 24
$532.8M
Q2 24
$420.9M
Q1 24
$453.9M
Q3 23
$295.8M
Total Assets
CD
CD
KROS
KROS
Q4 25
$338.0M
Q3 25
$742.8M
Q2 25
$36.6M
$757.2M
Q1 25
$784.6M
Q3 24
$579.3M
Q2 24
$455.0M
Q1 24
$485.8M
Q3 23
$326.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CD
CD
KROS
KROS
Operating Cash FlowLast quarter
$-1.3M
$107.5M
Free Cash FlowOCF − Capex
$106.0M
FCF MarginFCF / Revenue
27520.5%
Capex IntensityCapex / Revenue
402.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$239.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CD
CD
KROS
KROS
Q4 25
$107.5M
Q3 25
$3.2M
Q2 25
$-1.3M
$-29.6M
Q1 25
$161.2M
Q3 24
$-30.5M
Q2 24
$-39.8M
Q1 24
$-44.6M
Q3 23
$-34.0M
Free Cash Flow
CD
CD
KROS
KROS
Q4 25
$106.0M
Q3 25
$3.1M
Q2 25
$-30.3M
Q1 25
$160.6M
Q3 24
$-30.9M
Q2 24
$-40.1M
Q1 24
$-45.5M
Q3 23
$-34.5M
FCF Margin
CD
CD
KROS
KROS
Q4 25
27520.5%
Q3 25
21.9%
Q2 25
-167.0%
Q1 25
76.0%
Q3 24
-7960.3%
Q2 24
-108408.1%
Q1 24
-54826.5%
Q3 23
-431650.0%
Capex Intensity
CD
CD
KROS
KROS
Q4 25
402.9%
Q3 25
0.9%
Q2 25
4.0%
Q1 25
0.3%
Q3 24
99.5%
Q2 24
837.8%
Q1 24
1139.8%
Q3 23
6875.0%
Cash Conversion
CD
CD
KROS
KROS
Q4 25
Q3 25
Q2 25
Q1 25
1.09×
Q3 24
Q2 24
Q1 24
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons